Previous 10 | Next 10 |
NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...
AstraZeneca reports positive data for Phase III Farxiga trial AstraZeneca ( AZN ) reported that Farxiga has shown robust decline in the risk of kidney failure, cardiovascular or renal death in patients suffering from chronic kidney disease. The data from the Phase III DAPA-CKD trial show...
WILMINGTON, DE / ACCESSWIRE / September 1, 2020 / Rigrodsky & Long, P.A. announces that it is investigating Aimmune Therapeutics, Inc. ("Aimmune") (NASDAQ GS: AIMT ) regarding possible breaches of fiduciary duties and other violations of law related to Aimmune's agreement to be acquire...
NEW YORK, NY / ACCESSWIRE / August 31, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Monday was a mixed day on Wall Street, as the Dow Jones Industrial Average (DJINDICES: ^DJI) and S&P 500 (SNPINDEX: ^GSPC) lost ground despite another record showing for the Nasdaq Composite. Yet even with the losses for the day, the Dow and S&P were up around 8% in August, strin...
Gainers: Aimmune Therapeutics (NASDAQ: AIMT ) +171% . More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., Stocks on the move, Read more ...
Shares of Aimmune Therapeutics (NASDAQ: AIMT) jumped by an eye-popping 170% in pre-market trading Monday morning. The biotech's stock is screaming higher this morning in response to a $2.6 billion merger agreement -- on a fully diluted basis -- with Nestle 's (OTC: NSRGY) Health Science d...
Aimmune Therapeutics (NASDAQ: AIMT ) +171% on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . High profile stock splits Excitement is percolating around two of the market's favorite stocks as Apple (NASDAQ:AAPL) begins trading...
Nestle's ( OTCPK:NSRGY ) Health Scinece division (NHSc) has entered into a definitive agreement to acquire peanut allergy treatment maker Aimmune Therapeutics (NASDAQ: AIMT ) . More news on: Nestlé S.A., Aimmune Therapeutics, Inc., Nestlé S.A., Healthcare stocks news, Re...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
Aimmune Therapeutics Inc. Website:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...